{"id":"sglt2i","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Genital mycotic infections"},{"rate":"5-10","effect":"Urinary tract infections"},{"rate":"5-10","effect":"Polyuria"},{"rate":"0.1-0.2","effect":"Diabetic ketoacidosis"},{"rate":"3-5","effect":"Volume depletion"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 inhibitors work by inhibiting the SGLT2 transporter protein located in the proximal tubule of the kidney. This prevents the reabsorption of filtered glucose, leading to increased urinary glucose excretion (glucosuria) and lower blood glucose levels. Beyond glycemic control, SGLT2 inhibitors provide cardiovascular and renal protective effects through mechanisms including osmotic diuresis, improved insulin sensitivity, and reduced intraglomerular pressure.","oneSentence":"SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:54.377Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT07488689","phase":"PHASE3","title":"Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-07","conditions":"Septic Shock","enrollment":568},{"nctId":"NCT07491042","phase":"NA","title":"Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.","status":"RECRUITING","sponsor":"Oman Ministry of Health","startDate":"2026-04-01","conditions":"End Stage Chronic Renal Failure","enrollment":38},{"nctId":"NCT07471802","phase":"","title":"Monitoring of the Sympathetic/Vagal Balance Through Multiparametric Analysis of Heart Rate Variability (HRV)","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-03-25","conditions":"Diabete Type 2, Heart Failure, Kidney Disease, Chronic","enrollment":150},{"nctId":"NCT07157475","phase":"","title":"Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors","status":"RECRUITING","sponsor":"Wroclaw Medical University","startDate":"2025-07-01","conditions":"Peripheral Arterial Disease(PAD)","enrollment":300},{"nctId":"NCT07228195","phase":"PHASE4","title":"SGLT2i Therapy in Islet Transplantation (SIT)","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-05-15","conditions":"Partial Islet Function, TPIAT, Diabetes","enrollment":40},{"nctId":"NCT05663515","phase":"","title":"A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Pancreatic Cancer","enrollment":24000},{"nctId":"NCT07482020","phase":"PHASE2","title":"SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-03-01","conditions":"Atrial Fibrillation (AF), Hypertension","enrollment":66},{"nctId":"NCT07169422","phase":"NA","title":"Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2026-03-01","conditions":"Diabetic Kidney Disease, Type 2 Diabetes, Chronic Kidney Disease","enrollment":120},{"nctId":"NCT06364930","phase":"PHASE4","title":"SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-03-26","conditions":"Chronic Hepatitis B","enrollment":412},{"nctId":"NCT07273838","phase":"PHASE2","title":"Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-03-05","conditions":"Heart Failure, Acute Kidney Injury","enrollment":130},{"nctId":"NCT03878706","phase":"","title":"The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination","status":"RECRUITING","sponsor":"University of Athens","startDate":"2017-11-03","conditions":"Diabetes Mellitus, Type 2","enrollment":240},{"nctId":"NCT07053319","phase":"PHASE1","title":"SGLT2i, Pioglitazone, and Ketone Production in T2D","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-07-20","conditions":"Type 2 Diabetes","enrollment":64},{"nctId":"NCT07469943","phase":"","title":"The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness and Cardiac Deformation After Acute Myocardial Infarction","status":"RECRUITING","sponsor":"University of Athens","startDate":"2026-01-09","conditions":"Myocardial Infarction (MI), Diabete Type 2","enrollment":80},{"nctId":"NCT07465926","phase":"","title":"Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","status":"COMPLETED","sponsor":"Chung Shan Medical University","startDate":"2017-01-01","conditions":"Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease","enrollment":451036},{"nctId":"NCT07444203","phase":"","title":"Transformative Research in Diabetic Nephropathy 2.0","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-11-12","conditions":"Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic","enrollment":200},{"nctId":"NCT07434791","phase":"NA","title":"Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-03","conditions":"Diabetic Kidney Disease (DKD)","enrollment":100},{"nctId":"NCT07280585","phase":"PHASE3","title":"STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease","status":"RECRUITING","sponsor":"University of Cologne","startDate":"2025-12-16","conditions":"Polycystic Kidney, Autosomal Dominant","enrollment":420},{"nctId":"NCT07436663","phase":"PHASE4","title":"Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT06128980","phase":"PHASE2, PHASE3","title":"Withdrawal of Treatment for Heart Failure Patients With Recovery From Tachycardia-induced Cardiomyopathy","status":"RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2025-01-09","conditions":"Heart Failure With Reduced Ejection Fraction, Heart Rhythm Disorder","enrollment":348},{"nctId":"NCT07424430","phase":"","title":"Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes","status":"NOT_YET_RECRUITING","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2026-03","conditions":"Diabetes (DM), Type 2 Diabetes, Obesity (Disorder)","enrollment":400},{"nctId":"NCT06430684","phase":"EARLY_PHASE1","title":"Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2024-08-23","conditions":"Chronic Kidney Diseases, Pediatric Kidney Disease","enrollment":40},{"nctId":"NCT07044700","phase":"","title":"Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2028-01-31","conditions":"Heart Failure of Reduced Ejection Fraction (HFrEF)","enrollment":5000},{"nctId":"NCT05660083","phase":"PHASE2","title":"Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-01-12","conditions":"HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma","enrollment":36},{"nctId":"NCT06932081","phase":"","title":"Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2023-01-01","conditions":"Adult Congenital Heart Disease, Congenital Heart Disease, Systemic Right Ventricle","enrollment":400},{"nctId":"NCT05734690","phase":"PHASE4","title":"COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2023-05-05","conditions":"Heart Failure","enrollment":503},{"nctId":"NCT05834738","phase":"PHASE2","title":"Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-20","conditions":"IgA Nephropathy, Immunoglobulin A Nephropathy","enrollment":54},{"nctId":"NCT06625073","phase":"PHASE4","title":"Randomized Trial of SGLT2i in Heart Transplant Recipients","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-01-20","conditions":"Heart Transplant, Cardiovascular Disease, Kidney Disease","enrollment":200},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT07351643","phase":"PHASE4","title":"CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2026-02-25","conditions":"ACS (Acute Coronary Syndrome), SGLT2 Inhibitors","enrollment":110},{"nctId":"NCT07348484","phase":"","title":"Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Instituto de Investigación Biomédica de Salamanca","startDate":"2026-01","conditions":"Chronic Kidney Disease","enrollment":300},{"nctId":"NCT07055282","phase":"EARLY_PHASE1","title":"SGLT2i in Kidney Stones","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-11-20","conditions":"Kidney Stones","enrollment":32},{"nctId":"NCT07331220","phase":"NA","title":"Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-12-30","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":310},{"nctId":"NCT07325435","phase":"PHASE4","title":"Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists","status":"ACTIVE_NOT_RECRUITING","sponsor":"MaryAnn Banerji","startDate":"2024-12-21","conditions":"Type 2 Diabetes (T2DM)","enrollment":60},{"nctId":"NCT05882071","phase":"","title":"Non-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2023-11-15","conditions":"Diabetes Mellitus, Type 2","enrollment":547150},{"nctId":"NCT06528405","phase":"PHASE2","title":"The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-11-21","conditions":"Acute Kidney Injury","enrollment":264},{"nctId":"NCT06029712","phase":"PHASE2","title":"Heart Failure Polypill at a Safety Net Hospital","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2024-02-27","conditions":"Heart Failure With Reduced Ejection Fraction, HIV Infections","enrollment":35},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT06285760","phase":"","title":"Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY)","status":"RECRUITING","sponsor":"Puerta de Hierro University Hospital","startDate":"2024-03-01","conditions":"Heart Failure, Persistent Congestion","enrollment":64},{"nctId":"NCT07172971","phase":"PHASE1","title":"Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Larry W. Markham","startDate":"2026-02-01","conditions":"Duchenne Muscular Dystrophy (DMD)","enrollment":10},{"nctId":"NCT06609356","phase":"EARLY_PHASE1","title":"Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-07-03","conditions":"Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes","enrollment":27},{"nctId":"NCT07295522","phase":"PHASE4","title":"Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?","status":"NOT_YET_RECRUITING","sponsor":"IRCCS Policlinico S. Donato","startDate":"2026-01-08","conditions":"Heart Failure, Acute Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)","enrollment":368},{"nctId":"NCT07057479","phase":"PHASE3","title":"Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT07292909","phase":"PHASE4","title":"Effect of Empagliflozin on Inflammation","status":"RECRUITING","sponsor":"Hotel Dieu de France Hospital","startDate":"2025-09-01","conditions":"CAD - Coronary Artery Disease, Inflamation, PCI","enrollment":100},{"nctId":"NCT07272057","phase":"NA","title":"SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-12-07","conditions":"Lung Cancer","enrollment":200},{"nctId":"NCT05521984","phase":"PHASE1","title":"Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-04-03","conditions":"Pediatric Brain Tumor, Pediatric Solid Tumor","enrollment":20},{"nctId":"NCT07270198","phase":"NA","title":"Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression","status":"NOT_YET_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2026-02","conditions":"Diabetic Kidney Disease (DKD)","enrollment":100},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT06393348","phase":"PHASE2","title":"Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.","status":"COMPLETED","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2024-05-17","conditions":"Type 2 Diabetes","enrollment":155},{"nctId":"NCT05786443","phase":"PHASE2","title":"Safety and Efficacy of Empagliflozin in Hemodialysis","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-01-31","conditions":"End Stage Renal Disease","enrollment":60},{"nctId":"NCT06111768","phase":"PHASE2","title":"Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2024-05-30","conditions":"Cardiorenal Syndrome","enrollment":30},{"nctId":"NCT05402579","phase":"","title":"Diabetic Ketoacidosis From New SGLT2i: Can Genomics Estimate Risk","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2022-07-29","conditions":"Diabetes Type 2, DKA, Diabetic Ketoacidosis","enrollment":63},{"nctId":"NCT06183437","phase":"PHASE4","title":"The STOP-MED CTRCD Trial","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-03-04","conditions":"Heart Failure, Cardiotoxicity, Cardiac Toxicity","enrollment":335},{"nctId":"NCT06410352","phase":"PHASE4","title":"Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome","status":"RECRUITING","sponsor":"University Medical Center, Kazakhstan","startDate":"2024-03-01","conditions":"Metabolic Syndrome","enrollment":220},{"nctId":"NCT07110415","phase":"PHASE4","title":"Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction","status":"RECRUITING","sponsor":"SPH Qingdao Growful Pharmacetical Co.,Ltd","startDate":"2025-11-06","conditions":"Coronary Heart Disease, Cardiac Dysfunction","enrollment":2708},{"nctId":"NCT07244003","phase":"PHASE4","title":"Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-03-29","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":430},{"nctId":"NCT05390892","phase":"PHASE4","title":"PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-09-26","conditions":"Type2Diabetes, ASCVD","enrollment":6000},{"nctId":"NCT07241702","phase":"","title":"EFFECT OF HYBRID CLOSED-LOOP SYSTEMS ON CARDIOVASCULAR MARKERS IN TYPE 1 DIABETES.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Attikon Hospital","startDate":"2019-09-01","conditions":"Type 1 Diabetes","enrollment":100},{"nctId":"NCT05073692","phase":"","title":"Comparison of Type 2 Diabetes Pharmacotherapy Regimens","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2021-07-01","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Diseases","enrollment":241981},{"nctId":"NCT06171802","phase":"PHASE4","title":"EMPagliflozin After Aortic Valve Replacement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-02-14","conditions":"Aortic Valve Stenosis","enrollment":205},{"nctId":"NCT03188887","phase":"PHASE3","title":"Treatment of IgA Nephropathy According to Renal Lesions","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-20","conditions":"IgA Nephropathy","enrollment":62},{"nctId":"NCT05989503","phase":"PHASE4","title":"Initiation of ARNi and SGLT2i in Patients With HFrEF","status":"COMPLETED","sponsor":"Universidade do Porto","startDate":"2023-08-04","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":62},{"nctId":"NCT07056699","phase":"PHASE3","title":"SGLT2i, Pioglitazone, and Ketone Production in T1D","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-01-30","conditions":"Type1diabetes","enrollment":24},{"nctId":"NCT05090358","phase":"PHASE2","title":"Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-10-08","conditions":"Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer","enrollment":15},{"nctId":"NCT05214573","phase":"","title":"Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-12-01","conditions":"Type 2 Diabetes, Cardiac Disease","enrollment":386301},{"nctId":"NCT07211802","phase":"PHASE3","title":"CKM For Safe Use of SGLT2i in Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-07-01","conditions":"Type 1 Diabetes (T1D)","enrollment":52},{"nctId":"NCT06697353","phase":"","title":"An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-11-01","conditions":"Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction","enrollment":4936},{"nctId":"NCT06260059","phase":"PHASE4","title":"Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease","status":"RECRUITING","sponsor":"Anita Saraf","startDate":"2024-09-17","conditions":"Adult Congenital Heart Disease, Heart Failure","enrollment":40},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT06674109","phase":"PHASE4","title":"SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-10-15","conditions":"Gout and Hyperuricemia","enrollment":60},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT05180773","phase":"PHASE4","title":"Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy","status":"RECRUITING","sponsor":"Dennis M. McNamara, MD, MS","startDate":"2022-07-27","conditions":"Peripartum Cardiomyopathy, Postpartum","enrollment":250},{"nctId":"NCT05990296","phase":"NA","title":"Evaluating Strategies to Improve Guideline Directed Medical Therapy: The GDMT Research, Education & Assist Trial for Heart Failure Care","status":"COMPLETED","sponsor":"Geisinger Clinic","startDate":"2023-08-01","conditions":"Heart Failure, Heart Failure With Reduced Ejection Fraction","enrollment":4306},{"nctId":"NCT07146880","phase":"PHASE2","title":"Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-09-15","conditions":"Brugada Syndrome (BrS)","enrollment":10},{"nctId":"NCT05612594","phase":"PHASE4","title":"Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-03-27","conditions":"Sleep Apnea","enrollment":164},{"nctId":"NCT06520891","phase":"","title":"\"The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease\"","status":"RECRUITING","sponsor":"Fayoum University","startDate":"2024-06-01","conditions":"2 Drugs Are Statin and SGLT2i","enrollment":90},{"nctId":"NCT05278962","phase":"PHASE4","title":"HF Patients With LVADs Being Treated With SGLT2i","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2022-09-08","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":32},{"nctId":"NCT07143773","phase":"PHASE4","title":"SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2025-09-01","conditions":"Kidney Transplantation Recipients, Sodium-Glucose Transporter 2 Inhibitors, Non-Diabetic Patients","enrollment":88},{"nctId":"NCT05350202","phase":"","title":"Emp-Activity: Empagliflozin Functional Capacity","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-12-18","conditions":"Heart Failure","enrollment":3431},{"nctId":"NCT07119424","phase":"","title":"Multidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients: From Molecular Aspects to Clinical Indications","status":"RECRUITING","sponsor":"Chiara Lanzani","startDate":"2025-02-14","conditions":"Elderly Patients (>65 Years), Diabetes (DM), Heart Disease","enrollment":300},{"nctId":"NCT05033054","phase":"","title":"Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-01-01","conditions":"Kidney Disease, Chronic, Diabetes","enrollment":33},{"nctId":"NCT07105917","phase":"PHASE3","title":"SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08-01","conditions":"Acute Ischemic Stroke","enrollment":1050},{"nctId":"NCT07108985","phase":"PHASE4","title":"Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-09","conditions":"Diabetes Mellitus, Type 2, Hyperglycemia, Insulin Resistance","enrollment":100},{"nctId":"NCT06030843","phase":"PHASE2, PHASE3","title":"The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1","status":"RECRUITING","sponsor":"Chulalongkorn University","startDate":"2025-03-01","conditions":"Empagliflozin in Cardiorenal Syndrome Type 1","enrollment":200},{"nctId":"NCT05138575","phase":"PHASE2","title":"SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-01-24","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":53},{"nctId":"NCT06933355","phase":"PHASE4","title":"Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Odense University Hospital","startDate":"2025-03-27","conditions":"Kidney Transplantation Recipients, Magnetic Resonance Imaging (MRI), Sodium-Glucose Transporter 2 Inhibitors","enrollment":8},{"nctId":"NCT05986695","phase":"NA","title":"Informational Nudge to Improve Heart Failure Prescribing","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-06-09","conditions":"Heart Failure","enrollment":89},{"nctId":"NCT04735042","phase":"","title":"SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2020-10-07","conditions":"Type 2 Diabetes, Urinary Tract Infections","enrollment":60},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":"IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis","enrollment":585},{"nctId":"NCT07053293","phase":"EARLY_PHASE1","title":"SGLT2i, Hepatic Glucose Production, and SNS","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-01-07","conditions":"Type 2 Diabetes","enrollment":22},{"nctId":"NCT07060417","phase":"PHASE2","title":"Vascular Effects of SGLT2i in Non-diabetic CKD","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Non-diabetic Chronic Kidney Disease","enrollment":52},{"nctId":"NCT07053306","phase":"PHASE1","title":"SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-04-29","conditions":"Type 2 Diabetes","enrollment":29},{"nctId":"NCT06150924","phase":"PHASE2","title":"Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria","status":"COMPLETED","sponsor":"Mineralys Therapeutics Inc.","startDate":"2023-12-14","conditions":"Chronic Kidney Disease","enrollment":60},{"nctId":"NCT03282136","phase":"PHASE4","title":"SGLT2i and Incretin and CRTd.","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2017-09-01","conditions":"Type 2 Diabetes Mellitus, Heart Failure","enrollment":500},{"nctId":"NCT07032116","phase":"","title":"YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1","status":"NOT_YET_RECRUITING","sponsor":"Liu Hongfang","startDate":"2025-08-01","conditions":"Diabetic Kidney Disease (DKD)","enrollment":4472},{"nctId":"NCT06143566","phase":"PHASE1, PHASE2","title":"Polypill for Prevention of Cardiomyopathy","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-03-11","conditions":"Type 2 Diabetes, High Blood Pressure","enrollment":200},{"nctId":"NCT07019012","phase":"PHASE4","title":"Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.","status":"RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2025-07-30","conditions":"T2DM","enrollment":170},{"nctId":"NCT05966792","phase":"NA","title":"SGLT2 Inhibitors in Treating Patients With PCOS","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai 10th People's Hospital","startDate":"2023-11-10","conditions":"Polycystic Ovary Syndrome","enrollment":80},{"nctId":"NCT06453577","phase":"","title":"Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2023-05-01","conditions":"Acute Decompensated Heart Failure","enrollment":12},{"nctId":"NCT06983054","phase":"PHASE4","title":"DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2023-07-25","conditions":"Type 2 Diabetes","enrollment":34},{"nctId":"NCT05590143","phase":"PHASE4","title":"proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amsterdam UMC","startDate":"2023-06-09","conditions":"Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor","enrollment":784}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4330,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"SGLT2i","genericName":"SGLT2i","companyName":"University of Chicago","companyId":"university-of-chicago","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}